COMPANY

NeuroTherapia

HQ: Gates Mills, OH source · neurotherapia.com ↗ · Midwest

Keywords: neurology small molecule Alzheimer Disease Mild Cognitive Impairment Neuropathic Pain alzheimer's disease NTRX-07 NTRX-07-SDD

Location: Gates Mills, OH · source · Oct 15, 2026

Profile checked Oct 10, 2026

Funding and NIH signals

NIH award NIH awarded $1.21M (SBIR Phase II 1R44AG102269-01, new, notice Sep 8, 2026). NIH RePORTER 1R44AG102269-01 (Sep 8, 2026)
Evidence (1 event)
- Sep 8, 2026 · NIH RePORTER 1R44AG102269-01
  Organization: NEUROTHERAPIA, INC.; City/State: CLEVELAND, OH; Project number: 1R44AG102269-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-08; FY total cost (award amount): 1213723; Administering IC: National Institute on Aging; Project title: Preclinical toxicology in animals to prove the safety of a novel Alzheimer's Disease treatment; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Mar 1, 2025 Trial start Phase 2: A Study of NTRX-07 in Participants With Alzheimer's Disease source ↗
Sep 6, 2022 Trial start Phase 1: A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07 source ↗
Oct 10, 2019 Trial start Phase 1: Safety and Tolerability of NTRX-07 in Healthy Volunteers source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT07058688	A Study of NTRX-07 in Participants With Alzheimer's Disease	Phase 2	Recruiting	Mar 1, 2025	Dec 31, 2025 (estimated)
NCT06194552	A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07	Phase 1	Completed	Sep 6, 2022	May 31, 2023 (actual)
NCT04375436	Safety and Tolerability of NTRX-07 in Healthy Volunteers	Phase 1	Completed	Oct 10, 2019	May 15, 2020 (actual)

Annual award amounts. Total $1.2M.

Sep 8, 2026 NIH award 1R44AG102269-01 FY2026: $1,213,723 awarded for that fiscal year; activity R44 (SBIR); PI KIRALY, MARIANNA; recipient as written: NEUROTHERAPIA, INC., CLEVELAND, OH. Preclinical toxicology in animals to prov source ↗